MX2022004060A - The use of the agent for inducing immunity to sars-cov-2. - Google Patents

The use of the agent for inducing immunity to sars-cov-2.

Info

Publication number
MX2022004060A
MX2022004060A MX2022004060A MX2022004060A MX2022004060A MX 2022004060 A MX2022004060 A MX 2022004060A MX 2022004060 A MX2022004060 A MX 2022004060A MX 2022004060 A MX2022004060 A MX 2022004060A MX 2022004060 A MX2022004060 A MX 2022004060A
Authority
MX
Mexico
Prior art keywords
seq
cov
agent
sars
adenovirus serotype
Prior art date
Application number
MX2022004060A
Other languages
Spanish (es)
Inventor
Olga Popova
Aleksandr Sergeevich Semikhin
Olga Vadimovna Zubkova
Tatiana Andreevna Ozharovskaia
Inna Vadimovna Dolzhikova
Dmitrii Viktorovich Shchebliakov
Daria Mikhailovna Grousova
Alina Shahmirovna Dzharullaeva
Amir Ildarovich Tukhvatulin
Natalia Mikhailovna Tukhvatulina
Dmitrii Nikolaevich Shcherbinin
Ilias Bulatovich Esmagambetov
Elizaveta Alexandrovna Tokarskaya
Andrei Gennadevich Botikov
Denis Yuryevich Logunov
Aleksandr Leonidovich Gintsburg
Fatima Magomedovna Izhaeva
Nadezhda Leonidovna Lubenets
Boris Savelievich Naroditsky
Vladimir Aleksandrovich Chernetsov
Evgenii Vladimirovich Kriukov
Vladimir Fedorovich Babira
Alina Sergeevna Erokhova
Natalia Anatolievna Nikitenko
Dmitrii Anatolievich Kutaev
Svetlana Yakovlevna Loginova
Original Assignee
Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021104430A external-priority patent/RU2744442C1/en
Application filed by Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte filed Critical Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte
Publication of MX2022004060A publication Critical patent/MX2022004060A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Group of invention relates to biotechnology, immunology and virology. Described is the use of an agent containing expression vector based on strain human adenovirus serotype 26 or human adenovirus serotype 5, in which E1 and E3 regions are deleted, with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or simian adenovirus serotype 25, in which E1 and E3 regions are deleted with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3 or contains only component 2 for induction of specific immunity against severe acute respiratory syndrome Sars-CoV-2 in people over 60 and/or with chronic diseases. Also an agent can containing any two of said components. Invention provides effective induction of specific immunity against severe acute respiratory syndrome Sars-CoV-2 in people over 60 and/or with chronic diseases.
MX2022004060A 2021-02-21 2022-02-18 The use of the agent for inducing immunity to sars-cov-2. MX2022004060A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021104430A RU2744442C1 (en) 2021-02-21 2021-02-21 Use of agent for induction of specific immunity against severe acute respiratory syndrome sars-cov-2 for population revaccination in people over 60 and/or with chronic diseases (versions)
PCT/RU2022/000045 WO2022177465A1 (en) 2021-02-21 2022-02-18 The use of the agent for inducing immunity to sars-cov-2

Publications (1)

Publication Number Publication Date
MX2022004060A true MX2022004060A (en) 2022-09-19

Family

ID=82850909

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004060A MX2022004060A (en) 2021-02-21 2022-02-18 The use of the agent for inducing immunity to sars-cov-2.

Country Status (9)

Country Link
EP (1) EP4294439A1 (en)
JP (1) JP2023507543A (en)
KR (1) KR20230175091A (en)
CN (1) CN115226392A (en)
BR (1) BR112022005920A2 (en)
CA (1) CA3156448A1 (en)
IL (1) IL291803B1 (en)
MX (1) MX2022004060A (en)
ZA (1) ZA202203564B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2731342C9 (en) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Pharmaceutical agent and method for use thereof for inducing specific immunity to virus of severe acute respiratory syndrome sars-cov-2 (embodiments)

Also Published As

Publication number Publication date
IL291803B1 (en) 2024-03-01
ZA202203564B (en) 2023-11-29
BR112022005920A2 (en) 2023-11-07
IL291803A (en) 2022-06-01
EP4294439A1 (en) 2023-12-27
CN115226392A (en) 2022-10-21
CA3156448A1 (en) 2022-08-21
KR20230175091A (en) 2023-12-29
JP2023507543A (en) 2023-02-24

Similar Documents

Publication Publication Date Title
AR121931A1 (en) IMMUNOBIOLOGICAL AGENT AND METHOD OF USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS (VARIANTS)
McKinstry et al. Effector CD4 T-cell transition to memory requires late cognate interactions that induce autocrine IL-2
MX2022003069A (en) Agent for inducing specific immunity against sars-cov-2.
TR200201048T2 (en) Compositions for the prevention and treatment of cold and flu-like symptoms
NO20053860L (en) COP 1 for the treatment of inflammatory bowel disease.
BR0111366A (en) Recombinant Porcine Respiratory and Respiratory Syndrome Virus (prrsv) Vaccine
WO2020250209A3 (en) Lactoferrin for oral use with antiviral action
BR112022024470A2 (en) RECOMBINANT SARS-COV-2 ADENOVIRAL VECTOR VACCINE, USE OF A SARS-COV-2 PROTEIN S GENE AND USE OF A RECOMBINANT ADENOVIRUS
BR112021015751A2 (en) Gene therapy vectors for the treatment of danon's disease
BR112022026408A2 (en) VACCINE COMBINATION AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION
MX2022014931A (en) Methods of assessing risk of developing a severe response to coronavirus infection.
MX2021013947A (en) Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine.
MX2022004060A (en) The use of the agent for inducing immunity to sars-cov-2.
ZA202301438B (en) Aa v5-based vaccine against sars-cov-2
BR112017013270A2 (en) "dengue virus vaccine composition, methods for inducing a dengue immune response, reducing the likelihood of dengue infection, or preventing or alleviating dengue symptoms, and use of a dengue virus vaccine composition."
MX2022003963A (en) The use of the agent for inducing immunity to sars-cov-2.
MX2022004059A (en) Induction of immunity to sars-cov-2 in children.
Sokic et al. Risk factors for laryngeal cancer
ZA202202322B (en) Expression vector against severe acute respiratory syndrome virus sars-cov-2
UY39582A (en) VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SARSCOV-2 AND/OR THE PREVENTION OF SARSCOV-2 RELATED CORONAVIRUS INFECTION
ZA202202321B (en) Pharmaceutical agent for inducing specific immunity against sars-cov-2
BRPI0513118A (en) recombinant marek virus, vaccine and use of a virus
BR112022004778A2 (en) AGENT FOR SPECIFIC IMMUNITY INDUCTION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARSCOV-2 IN LYOPHILIZED FORM (VARIANTS) AND USE
AR124744A1 (en) AGENT FOR USE IN INDUCING SPECIFIC IMMUNITY AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS IN SUBJECTS OVER 60 YEARS OF AGE AND/OR HAVING CHRONIC DISEASES (VARIANTS)
MX2022000232A (en) Compositions and methods of treating or preventing ocular infections with filociclovir.